| Angiotensin-converting enzyme 2: central regulator for cardiovascular function. | |
| | |
MedLine Citation:
|
PMID: 20424953 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Angiotensin-converting enzyme 2 (ACE2) is a new component of the renin-angiotensin system (RAS). Accumulating evidence shows that ACE2 provides protective effects in peripheral tissues and has great potential for the treatment of RAS-related diseases. The role of ACE2 in the central nervous system is not well established. However, in recent years, much more progress has been made on the studies of this carboxypeptidase in the central regulation of blood pressure and cardiovascular function in general. It has been shown that brain ACE2 interacts with the other components of the RAS (ACE, angiotensin II, and angiotensin II type 1 receptor), protects baroreflex and autonomic function, stimulates nitric oxide release, reduces oxidative stress, and prevents the development of or attenuates hypertension. These data support the critical role of ACE2 in the central regulation of cardiovascular function. This review summarizes recently published data on the central effects of ACE2 in the regulation of cardiovascular function. |
| | |
Authors:
|
Huijing Xia; Eric Lazartigues |
Related Documents
:
|
16199473 - Chronic angiotensin ii at1 receptor blockade increases cerebral cortical microvessel de... 17272743 - Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction cau... 38623 - The long-term hypotensive effect of timolol maleate compared with the effect of pilocar... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Current hypertension reports Volume: 12 ISSN: 1534-3111 ISO Abbreviation: Curr. Hypertens. Rep. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-26 Completed Date: 2011-06-02 Revised Date: 2012-05-09 |
Medline Journal Info:
|
Nlm Unique ID: 100888982 Medline TA: Curr Hypertens Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 170-5 Citation Subset: IM |
Affiliation:
|
School of Medicine, Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, 1901 Perdido Street, Room 5218, New Orleans, LA 70112, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Autonomic Nervous System
/
enzymology,
physiopathology Baroreflex Carboxypeptidases / metabolism Cardiovascular Diseases / enzymology, physiopathology Cardiovascular Physiological Processes* Cardiovascular System / enzymology* Humans Hypertension / enzymology, physiopathology Nitric Oxide Nitric Oxide Synthase / metabolism Oxidative Stress Peptidyl-Dipeptidase A / metabolism, physiology* Renin-Angiotensin System / physiology* |
| Grant Support | |
ID/Acronym/Agency:
|
HL093178/HL/NHLBI NIH HHS; NS052479/NS/NINDS NIH HHS; R01 HL093178/HL/NHLBI NIH HHS; R01 HL093178-03/HL/NHLBI NIH HHS; RR018766/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
10102-43-9/Nitric Oxide; EC 1.14.13.39/Nitric Oxide Synthase; EC 3.4.-/Carboxypeptidases; EC 3.4.15.1/Peptidyl-Dipeptidase A; EC 3.4.17.-/angiotensin converting enzyme 2 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Baroreflex stimulation in antihypertensive treatment.
Next Document: Oxidative stress and vascular function: implications for pharmacologic treatments.